top of page

- Jun 17, 2017

Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.

View PDF Version

Ph2_NT501_CNTF

.pdf

Download PDF • 159KB

Recent Posts

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel

Neurotech Chief Medical Officer authors article in The Ophthalmologist

bottom of page